Integra LifeSciences (NASDAQ:IART) Releases Q4 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its fourth quarter earnings guidance on Monday. The company provided earnings per share guidance of $0.81-0.89 for the period, compared to the consensus earnings per share estimate of $0.87. The company issued revenue guidance of $441-451 million, compared to the consensus revenue estimate of $448.48 million. Integra LifeSciences also updated its FY 2024 guidance to 2.410-2.490 EPS.

Integra LifeSciences Stock Performance

IART traded up $5.14 on Monday, hitting $24.42. 890,903 shares of the stock traded hands, compared to its average volume of 1,085,863. The business has a fifty day moving average price of $18.62 and a two-hundred day moving average price of $24.52. The company has a current ratio of 3.39, a quick ratio of 2.10 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $1.89 billion, a PE ratio of 80.34, a P/E/G ratio of 0.64 and a beta of 1.08. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $45.42.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. JMP Securities dropped their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. Morgan Stanley raised their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a report on Monday, July 15th. Citigroup reduced their price target on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating for the company in a report on Tuesday, October 1st. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Finally, Truist Financial reduced their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research note on Monday, October 14th. Three analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $26.50.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.